Hikal Limited (BSE: 524735)
Health Care · Pharmaceuticals · IN
Rs213.45
-2.15% today · -14.0% 1Y
Hikal Limited (BSE: 524735) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $271.94M.
Over the last twelve months the share price has lost 14.0%, trading between 145.95 and 260.80.
Tweenvest scores Hikal Limited across four factors: quality 64/100, value 58/100, growth 9/100, dividend 5/100. Its strongest factor is quality.
524735 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $271.94M
- Revenue (TTM)
- $183.50M
- P/E
- —
- EPS
- -2.74
- Dividend yield
- 0.28%
- Beta (5Y)
- 0.57
- 52-week high
- Rs260.80
- 52-week low
- Rs145.95
- Avg volume (3M)
- —
- Shares outstanding
- 123.30M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Antengene Corporation LimitedSEHK: 6996 | $279.47M | HK$3.19 | -4.06% |
| Elite Pharmaceuticals, Inc.OTCPK: ELTP | $274.78M | $0.26 | -3.74% |
| AFT Pharmaceuticals LimitedNZSE: AFT | $272.98M | NZ$4.64 | +6.18% |
| Pharmasaga Co. Ltd.TPEX: 7878 | $272.92M | NT$163.00 | -2.10% |
| Duopharma Biotech BerhadKLSE: DPHARMA | $266.04M | RM1.13 | -0.88% |
| Fredun Pharmaceuticals LimitedBSE: 539730 | $265.41M | Rs1,553.15 | +14.79% |
| Guangdong Jiaying Pharmaceutical Co., LtdSZSE: 002198 | $263.47M | CN¥3.55 | -0.84% |
| Hunan Nucien Pharmaceutical Co., Ltd.SHSE: 688189 | $261.09M | CN¥6.41 | -0.47% |
Figures last refreshed Oct 11, 2026.